WO2018182172A1 - 환경오염 물질에 대한 세포 보호 효과를 갖는 펩타이드 및 이의 용도 - Google Patents
환경오염 물질에 대한 세포 보호 효과를 갖는 펩타이드 및 이의 용도 Download PDFInfo
- Publication number
- WO2018182172A1 WO2018182172A1 PCT/KR2018/001953 KR2018001953W WO2018182172A1 WO 2018182172 A1 WO2018182172 A1 WO 2018182172A1 KR 2018001953 W KR2018001953 W KR 2018001953W WO 2018182172 A1 WO2018182172 A1 WO 2018182172A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- amino acid
- peptide
- dioxin
- acid sequence
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 93
- 239000003344 environmental pollutant Substances 0.000 title abstract description 13
- 230000001120 cytoprotective effect Effects 0.000 title abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 64
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 claims abstract description 45
- 150000002013 dioxins Chemical class 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims description 28
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 18
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 16
- 235000013305 food Nutrition 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000002537 cosmetic Substances 0.000 claims description 13
- 230000000185 dioxinlike effect Effects 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 8
- 150000003071 polychlorinated biphenyls Chemical group 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 4
- 206010057644 Testis cancer Diseases 0.000 claims description 4
- 201000006828 endometrial hyperplasia Diseases 0.000 claims description 4
- 201000003120 testicular cancer Diseases 0.000 claims description 4
- 201000004384 Alopecia Diseases 0.000 claims description 3
- 208000032170 Congenital Abnormalities Diseases 0.000 claims description 3
- 206010010356 Congenital anomaly Diseases 0.000 claims description 3
- 206010019851 Hepatotoxicity Diseases 0.000 claims description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 3
- 206010030113 Oedema Diseases 0.000 claims description 3
- 206010037660 Pyrexia Diseases 0.000 claims description 3
- 208000025865 Ulcer Diseases 0.000 claims description 3
- 208000024248 Vascular System injury Diseases 0.000 claims description 3
- 208000012339 Vascular injury Diseases 0.000 claims description 3
- 230000007698 birth defect Effects 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 208000024963 hair loss Diseases 0.000 claims description 3
- 230000003676 hair loss Effects 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000304 hepatotoxicity Toxicity 0.000 claims description 3
- 230000007686 hepatotoxicity Effects 0.000 claims description 3
- 230000036737 immune function Effects 0.000 claims description 3
- 231100000397 ulcer Toxicity 0.000 claims description 3
- 230000004580 weight loss Effects 0.000 claims description 3
- 208000001348 Chloracne Diseases 0.000 claims description 2
- 230000003042 antagnostic effect Effects 0.000 claims description 2
- 230000000740 bleeding effect Effects 0.000 claims description 2
- 150000004826 dibenzofurans Chemical class 0.000 claims description 2
- 208000017520 skin disease Diseases 0.000 claims description 2
- NFBOHOGPQUYFRF-UHFFFAOYSA-N oxanthrene Chemical class C1=CC=C2OC3=CC=CC=C3OC2=C1 NFBOHOGPQUYFRF-UHFFFAOYSA-N 0.000 claims 2
- 206010019842 Hepatomegaly Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000428 dust Substances 0.000 abstract description 16
- 238000000034 method Methods 0.000 abstract description 10
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 abstract description 8
- 230000007246 mechanism Effects 0.000 abstract description 6
- 230000004913 activation Effects 0.000 abstract description 5
- 231100000419 toxicity Toxicity 0.000 abstract description 5
- 230000001988 toxicity Effects 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 230000004888 barrier function Effects 0.000 abstract description 3
- 231100000223 dermal penetration Toxicity 0.000 abstract 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 description 28
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 15
- 102000008142 Cytochrome P-450 CYP1A1 Human genes 0.000 description 14
- 108010074918 Cytochrome P-450 CYP1A1 Proteins 0.000 description 14
- -1 dioxins (polychlorinated dibenzo- p- dioxin Chemical class 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 230000005937 nuclear translocation Effects 0.000 description 11
- 239000011347 resin Substances 0.000 description 9
- 229920005989 resin Polymers 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 238000003757 reverse transcription PCR Methods 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 210000002510 keratinocyte Anatomy 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 239000003642 reactive oxygen metabolite Substances 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 230000017111 nuclear migration Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000011191 terminal modification Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 3
- 102000008056 Aryl Hydrocarbon Receptor Nuclear Translocator Human genes 0.000 description 3
- 108010049386 Aryl Hydrocarbon Receptor Nuclear Translocator Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 230000000711 cancerogenic effect Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000013618 particulate matter Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical group C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 description 2
- 102100030157 Microphthalmia-associated transcription factor Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 2
- 238000010805 cDNA synthesis kit Methods 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 231100000719 pollutant Toxicity 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- MGHMWKZOLAAOTD-DEOSSOPVSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(1h-indol-3-yl)propanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(=O)O)CC1=CNC2=CC=CC=C12 MGHMWKZOLAAOTD-DEOSSOPVSA-N 0.000 description 1
- JAUKCFULLJFBFN-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-VWLOTQADSA-N 0.000 description 1
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 1
- GVIXTVCDNCXXSH-AWEZNQCLSA-N (2s)-2-amino-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]pentanoic acid Chemical compound OC(=O)[C@@H](N)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C GVIXTVCDNCXXSH-AWEZNQCLSA-N 0.000 description 1
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- MZWJRVXBVNWTMX-UHFFFAOYSA-N 2,3,4,5,6-penta(nonyl)phenol Chemical class CCCCCCCCCC1=C(O)C(CCCCCCCCC)=C(CCCCCCCCC)C(CCCCCCCCC)=C1CCCCCCCCC MZWJRVXBVNWTMX-UHFFFAOYSA-N 0.000 description 1
- BUOYTFVLNZIELF-UHFFFAOYSA-N 2-phenyl-1h-indole-4,6-dicarboximidamide Chemical compound N1C2=CC(C(=N)N)=CC(C(N)=N)=C2C=C1C1=CC=CC=C1 BUOYTFVLNZIELF-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102100027456 Cytochrome c oxidase subunit 2 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 206010015993 Eyelid oedema Diseases 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 1
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 238000013381 RNA quantification Methods 0.000 description 1
- 231100000991 Reactive Oxygen Species (ROS) Photosafety Assay Toxicity 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- TXVHTIQJNYSSKO-UHFFFAOYSA-N benzo[e]pyrene Chemical class C1=CC=C2C3=CC=CC=C3C3=CC=CC4=CC=C1C2=C34 TXVHTIQJNYSSKO-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 231100000693 bioaccumulation Toxicity 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000004827 dibenzo-1,4-dioxins Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 231100000049 endocrine disruptor Toxicity 0.000 description 1
- 239000000598 endocrine disruptor Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000002803 fossil fuel Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000011133 lead Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003011 styrenyl group Chemical class [H]\C(*)=C(/[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000004056 waste incineration Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a peptide having a cell protective effect against an environmental pollutant and its use.
- Environmental pollutants are classified as so-called endocrine disruptors, and their types include organochlorine-based substances including dioxins, pesticides, phthalates, benzopyrenes, penta-nonyl phenols, bisphenol A, heavy metals, styrene dimers and trimers. These substances are very chemically stable, have a long time in the environment and have high bioaccumulation, which leads to the human body through the food chain.
- dioxin is a chlorinated hydrocarbon compound, and generally refers to dioxins (polychlorinated dibenzo- p- dioxin (PCDD) and furan (polychlorinated dibenzofuran (PCDF)) having similar chemical structures.
- PCDD and 135 PCDF isomers exist.
- Fine dust is composed of sulfurous acid gas, nitrogen oxide, lead, ozone, carbon monoxide, etc., and the particle size is fine dust with diameter of 10um or less, PM10. If the particle diameter is 2.5um or less, it is called ultrafine dust, PM2.5.
- the natural causes of fine dust include soil dust, salt from sea water, pollen of plants, etc.
- the causes of artificial dust are fumes from burning fossil fuels, automobile exhaust, flying dust from construction sites, raw materials in powder form in factories, Subsidiary materials, and incineration smoke.
- Phenoic aromatic hydrocarbons contained in dioxins and fine dusts are known to infiltrate cells and commonly activate the aryl hydrocarbon receptor (AhR).
- AhR activation mechanism increases intracellular reactive oxygen species (ROS), and AhR, ARNT heterodimer complexes bind to the xenobiotic response element (XRE) in the nucleus for various inflammations.
- ROS reactive oxygen species
- XRE xenobiotic response element
- MITf microphthalmia-associated transcription factor
- MMPs matrix metalloproteases
- Previously released anti-pollutants used materials to prevent the adsorption of fine dust to the skin or to strengthen the skin barrier. This does not prevent the direct mechanism of action of environmental pollutants such as dioxin or fine dust, but has an indirect protective effect. If environmental pollutants directly affect skin and affect skin cells, no raw materials or products have been developed that inhibit them.
- TCDD 2,3,7,8-tetrachlorodibenzodioxin
- Another object of the present invention is to provide a pharmaceutical composition for preventing or treating a disease caused by a dioxin-like substance comprising at least one member selected from the group consisting of peptides consisting of amino acid sequences of SEQ ID NO: 1, 2 or 3 .
- Another object of the present invention is to alleviate diseases caused by dioxin-like substances comprising as an active ingredient at least one peptide selected from the group consisting of peptides consisting of the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3 It is to provide a food composition for improvement.
- Another object of the present invention to provide a cosmetic composition for improving skin conditions comprising at least one selected from the group consisting of peptides consisting of the amino acid sequence of SEQ ID NO: 1, 2 or 3.
- Another object of the present invention is to provide a method for preventing or treating a disease caused by a dioxin analog.
- Another object of the invention relates to the use of the prophylaxis or treatment of diseases caused by dioxin analogs of peptides consisting of the amino acid sequence of SEQ ID NO: 1, 2, or 3.
- the present invention relates to a peptide having a cell protective effect against environmental pollutants and its use, wherein the peptide consisting of the amino acid sequence of SEQ ID NO: 1, 2 or 3 is known to be the most toxic among dioxin series 2,3,7, Direct binding to 8-tetrachlorodibenzodioxin (hereinafter TCDD) prevents penetration into the skin and prevents AhR activation mechanism by polycyclic aromatic hydrocarbons contained in TCDD and fine dust. For example, the effect of cell protection on these direct pollutants is indirectly different from existing methods of indirectly preventing opportunities for contact with the substance or reducing toxicity by strengthening barriers.
- TCDD 8-tetrachlorodibenzodioxin
- One aspect of the invention relates to a peptide consisting of the amino acid sequence of SEQ ID NO: 1, 2 or 3.
- the peptide may be one in which N-terminal and / or C-terminal modifications are induced to select a portion of an amino acid sequence and increase its activity.
- N-terminal and / or C-terminal modifications can significantly improve the stability of the peptides of the present invention and, for example, increase the half-life upon in vivo administration of the peptides.
- the N-terminal modification is an acetyl group, fluorenylmethoxycarbonyl group, formyl group, palmitoyl group, myristyl group at the N-terminus of the peptide.
- a stearyl group, and a polyethylene glycol (PEG) may be combined with a protecting group selected from the group consisting of.
- the protecting group serves to protect the peptide of the present invention from the attack of protein cleavage enzymes in vivo.
- the C-terminal modification may be a combination of a hydroxyl group (-OH), an amino group (amino group, -NH2), azide (azide, -NHNH2), etc. to the C-terminal end of the peptide, but is not limited thereto. .
- the peptide consisting of the amino acid sequence of SEQ ID NO: 1, 2 or 3 is 2,3,7,8-tetrachlorodibenzodioxin (hereinafter referred to as TCDD) which is known to be the most toxic among the dioxins family It binds directly to and prevents penetration into the skin, and prevents AhR activation mechanism by polycyclic aromatic hydrocarbons contained in TCDD and fine dust.
- TCDD 2,3,7,8-tetrachlorodibenzodioxin
- Polycyclic aromatic hydrocarbons introduced into the cell are combined with AhR, move into the nucleus, form a complex with AHR nuclear translocator (ARNT), attach to a dioxin-responsive element (DRE), and promote the expression of subgenes.
- Subgenes include CYP1A1 and several inflammation related factors. CYP1A1 is involved in the metabolism of several carcinogenic progenitors such as benzopyrene, and these metabolites are known to react with DNA and cause mutations. In addition, the expression of inflammation-related factors such as COX2, TNF-a and IL-1b may be increased to cause inflammatory responses in the contact area and systemic.
- Another aspect of the invention relates to a pharmaceutical composition for preventing or treating a disease caused by a dioxin analogue comprising at least one peptide selected from the group consisting of peptides consisting of amino acid sequences of SEQ ID NOs: 1, 2 or 3 .
- Diseases caused by the dioxin-like substance are very complex, skin diseases such as chlorine acne, sperm count, testicular cancer, prostate cancer, endometrial hyperplasia, breast cancer, hepatotoxicity, reduced immune function, hyperlipidemia, lower urethral fever, incubation It may include, but is not limited to, birth defects, vascular injuries, hepatocellular carcinoma, hypertrophy of the liver, adenofibrosis, weight loss, hair loss, oral edema, bleeding, or gastric mucosal ulcers. (Carter et al., Science 188: 738 (1975); Fourth Annual Report on Carcinogens, NTP 85-002: 170, 185 (1985)).
- TCDD 2,3,7,8-tetrachlorodibenzodioxin
- PCDD polychlorinated dibenzo-p-dioxin
- PCDFs polychlorinated dibenzofuran
- PCBs polychlorinated biphenyls
- dioxin refers to all compounds included in the PCDD, and "dioxin-like substance" includes the above-described PCDD, PCDFs and PCBs, and exhibits the same cellular effect as PCDD. Means.
- Dioxins are carcinogenic substances that have been reported to cause serious diseases such as reproductive and developmental disturbances, damage to the immune system and interference with hormonal regulation (Yang, JH et al., Carcinogenesis. 20: 13-18 (1999). ), Lee, YW et al., Toxicol. Lett., 102-103: 29-83 (1998).
- the pharmaceutical composition may include a pharmaceutically effective amount of at least one peptide selected from the group consisting of peptides consisting of the amino acid sequences of SEQ ID NO: 1, 2 or 3.
- the pharmaceutical composition may further comprise a pharmaceutically acceptable carrier.
- the pharmaceutically acceptable carrier is conventionally used in the preparation, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, Polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).
- the pharmaceutical composition of the present invention may further include, but is not limited to, a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, and the like.
- the pharmaceutical composition may be administered orally or parenterally, preferably parenterally, and in the case of parenteral administration, may be administered by intramuscular injection, intravenous injection, subcutaneous injection, intraperitoneal injection, topical administration, transdermal administration, or the like. It is not limited to this.
- the dosage of the pharmaceutical composition may be 0.0001 to 1000 ug per day (microgram, 0.001 to 1000 ug, 0.01 to 1000 ug, 0.1 to 1000 ug, or 1.0 to 1000 ug, but is not limited thereto. It may be prescribed in various ways by factors such as method, mode of administration, age, weight, sex, pathological condition, food, time of administration, route of administration, rate of excretion and response to response of the patient.
- the pharmaceutical composition may be prepared in unit dose form by formulating with a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person skilled in the art. It can be prepared by incorporation into a multi-dose container.
- the formulations may be in the form of solutions, suspensions or emulsions in oils or aqueous media, or in the form of extracts, powders, granules, tablets or capsules, and may further comprise dispersants and / or stabilizers.
- Another aspect of the present invention is directed to an antagonistic food composition for a dioxin analogue comprising at least one peptide selected from the group consisting of a peptide consisting of the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3 as an active ingredient It is about.
- Another aspect of the present invention is to alleviate a disease caused by a dioxin-like material comprising at least one peptide selected from the group consisting of the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3 as an active ingredient And / or a food composition for improvement.
- Diseases caused by the dioxin-like substance include sperm count, testicular cancer, prostate cancer, endometrial hyperplasia, breast cancer, hepatotoxicity, decreased immune function, hyperlipidemia, subesophageal fever, latent, birth defects, vascular injury, hepatocellular carcinoma, liver It may include, but is not limited to, hypertrophy, fibrosis, weight loss, hair loss, oral edema, eyelid edema, or gastric mucosal ulcer.
- the food may be various foods, beverages, food additives and the like.
- the content of the peptide as an active ingredient contained in the food composition is not particularly limited according to the form of the food, the desired use, etc., for example, may be added to 0.01 to 15% by weight of the total food weight, health beverage composition It can be added at a ratio of 0.02 to 10 g, preferably 0.3 to 1 g based on 100 ml of silver.
- the food is a beverage
- the liquid component in addition to containing the peptide as an essential ingredient in the indicated ratio, there are no particular limitations on the liquid component, and may contain various flavors or natural carbohydrates as additional ingredients as in general beverages.
- the natural carbohydrates are monosaccharides such as disaccharides such as glucose, fructose and the like, and conventional sugars and xylitol such as maltose, sucrose and the like, and polysaccharides such as dextrin, cyclodextrin and the like.
- Sugar alcohols such as sorbitol and erythritol.
- natural flavoring agents such as, tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used.
- the proportion of natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.
- the food composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof, alginic acid and Salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like.
- the food composition of the present invention may contain a fruit flesh for producing natural fruit juice and fruit juice beverage and vegetable beverage.
- These components can be used independently or in combination.
- the proportion of such additives is not so critical but is generally selected from the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.
- Another aspect of the present invention relates to a cosmetic composition for improving skin conditions comprising at least one member selected from the group consisting of peptides consisting of the amino acid sequences of SEQ ID NO: 1, 2 or 3.
- the cosmetic composition comprises (a) a cosmetically effective amount of the above-described peptide of the present invention; And / or (b) a cosmetically acceptable carrier, but is not limited thereto.
- cosmetic effective amount means an amount sufficient to achieve the skin condition improving efficacy of the composition of the present invention described above.
- the cosmetic composition may be prepared in any formulation commonly prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing, oils It may be formulated as powder foundation, emulsion foundation, wax foundation, spray, and the like, but is not limited thereto. More specifically, it may be prepared in the form of a flexible lotion, nutrition lotion, nutrition cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.
- the carrier components include animal oil, vegetable oil, wax, paraffin, starch, trakant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide. Can be used.
- the cosmetic formulation of the present invention is a powder or a spray
- lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular, in the case of a spray, additionally chlorofluorohydrocarbon.
- Propellant such as propane / butane or dimethyl ether.
- a solvent, solubilizer or emulsifier is used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol , Fatty acid esters of 1,3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
- the cosmetic formulation of the present invention is a suspension
- a liquid diluent such as water, ethanol or propylene glycol
- suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Microcrystalline cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
- the carrier component is aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, Fatty acid amide ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
- the components included in the cosmetic composition of the present invention include components commonly used in cosmetic compositions, in addition to peptides and carrier components as active ingredients, and include, for example, antioxidants, stabilizers, solubilizers, vitamins, pigments and flavorings. Such conventional adjuvants may be included.
- the term "improvement of skin condition” means a process of treating, alleviating, or alleviating damage to skin caused by an intrinsic or exogenous factor of the skin, or an effect thereof, for example, in skin It may be interpreted to exhibit the effect of alleviating, improving, or the like, but is not limited thereto.
- Another aspect of the invention relates to a method of preventing or treating a disease caused by a dioxin analog.
- the prophylactic or therapeutic method may include contacting a subject with a pharmaceutical composition comprising one or more peptides selected from the group consisting of peptides consisting of amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3 .
- the pharmaceutical composition is as described above.
- Another aspect of the invention relates to the use of the prophylaxis or treatment of a disease caused by a dioxin analog of a peptide consisting of the amino acid sequence of SEQ ID NO: 1, 2, or 3.
- the peptide consisting of the amino acid sequence of SEQ ID NO: 1, 2, or 3 is the same as described.
- peptide herein refers to a linear molecule formed by binding amino acid residues to each other by peptide bonds.
- the peptides of the present invention may be prepared by chemical synthesis methods known in the art, in particular solid-phase synthesis techniques (Merrifield, J. Amer. Chem. Soc. 85: 2149-54 (1963); Stewart, et al., Solid Phase Peptide Synthesis, 2nd. Ed., Pierce Chem. Co .: Rockford, 111 (1984)) or liquid phase synthesis technology (US Pat. No. 5,516,891).
- the term “stability” refers to in vivo stability as well as storage stability (eg, room temperature storage stability).
- the term "pharmaceutically effective amount” means an amount sufficient to achieve the efficacy or activity of the aforementioned peptides.
- the present invention relates to a peptide having a cell protective effect against environmental pollutants and its use, wherein the peptide consisting of the amino acid sequence of SEQ ID NO: 1, 2 or 3 is known to be the most toxic among dioxin series 2,3,7, Direct binding to 8-tetrachlorodibenzodioxin (hereinafter TCDD) prevents penetration into the skin and prevents AhR activation mechanism by polycyclic aromatic hydrocarbons contained in TCDD and fine dust. For example, the effect of cell protection on these direct pollutants is indirectly different from existing methods of indirectly preventing opportunities for contact with the substance or reducing toxicity by strengthening barriers.
- TCDD 8-tetrachlorodibenzodioxin
- Figure 1a is a graph showing the binding force to TCDD of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 according to an embodiment of the present invention.
- Figure 1b is a graph showing the binding force to TCDD of the peptide consisting of the amino acid sequence of SEQ ID NO: 2 according to an embodiment of the present invention.
- Figure 1c is a graph showing the binding force to TCDD of the peptide consisting of the amino acid sequence of SEQ ID NO: 3 according to an embodiment of the present invention.
- Figure 2a is a diagram showing the AhR nuclear translocation test results of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 according to an embodiment of the present invention.
- Figure 2b is a graph showing the AhR nuclear translocation test results of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 according to an embodiment of the present invention.
- Figure 2c is a diagram showing the AhR nuclear translocation test results of the peptide consisting of the amino acid sequence of SEQ ID NO: 2 according to an embodiment of the present invention.
- Figure 2d is a graph showing the AhR nuclear translocation test results of the peptide consisting of the amino acid sequence of SEQ ID NO: 2 according to an embodiment of the present invention.
- Figure 2e is a diagram showing the AhR nuclear translocation test results of the peptide consisting of the amino acid sequence of SEQ ID NO: 3 according to an embodiment of the present invention.
- Figure 2f is a graph showing the AhR nuclear translocation test results of the peptide consisting of the amino acid sequence of SEQ ID NO: 3 according to an embodiment of the present invention.
- Figure 3a is a graph showing the TCDD ICC results of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 according to an embodiment of the present invention.
- Figure 3b is a graph showing the TCDD ICC results of the peptide consisting of the amino acid sequence of SEQ ID NO: 2 according to an embodiment of the present invention.
- Figure 3c is a graph showing the TCDD ICC results of the peptide consisting of the amino acid sequence of SEQ ID NO: 3 according to an embodiment of the present invention.
- Figure 4a is a graph showing the results of intracellular ROS analysis of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 according to an embodiment of the present invention.
- Figure 4b is a graph showing the results of intracellular ROS analysis of the peptide consisting of the amino acid sequence of SEQ ID NO: 2 according to an embodiment of the present invention.
- Figure 4c is a graph showing the results of intracellular ROS analysis of the peptide consisting of the amino acid sequence of SEQ ID NO: 3 according to an embodiment of the present invention.
- Figure 5a is a graph showing the CYP1A1 and inflammatory molecule RT-PCR results of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 according to an embodiment of the present invention.
- Figure 5b is a graph showing the CYP1A1 and inflammatory molecule RT-PCR results of the peptide consisting of the amino acid sequence of SEQ ID NO: 2 according to an embodiment of the present invention.
- Figure 5c is a graph showing the results of CYP1A1 and inflammatory molecules RT-PCR of the peptide consisting of the amino acid sequence of SEQ ID NO: 3 according to an embodiment of the present invention.
- Figure 6a is a graph showing the AhR nuclear translocation test results of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 according to an embodiment of the present invention.
- Figure 6b is a graph showing the AhR nuclear translocation test results of the peptide consisting of the amino acid sequence of SEQ ID NO: 2 according to an embodiment of the present invention.
- Figure 6c is a graph showing the AhR nuclear translocation test results of the peptide consisting of the amino acid sequence of SEQ ID NO: 3 according to an embodiment of the present invention.
- Figure 7a is a graph showing the CYP1A1 and inflammatory molecule RT-PCR results of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 according to an embodiment of the present invention.
- Figure 7b is a graph showing the CYP1A1 and inflammatory molecule RT-PCR results of the peptide consisting of the amino acid sequence of SEQ ID NO: 2 according to an embodiment of the present invention.
- Figure 7c is a graph showing the CYP1A1 and inflammatory molecule RT-PCR results of the peptide consisting of the amino acid sequence of SEQ ID NO: 3 according to an embodiment of the present invention.
- chloro trityl chloride resin (CTC resin, Nova biochem Cat No. 01-64-0021) was added to a reaction vessel, and 490 ml of methylene chloride (MC) was added thereto, followed by stirring for 3 minutes. Then, the solution was removed, 490 ml of dimethylformamide (DMF) was added thereto, stirred for 3 minutes, and then the solvent was removed again.
- CTC resin chloro trityl chloride resin
- MC methylene chloride
- DMF dimethylformamide
- the deprotection reaction was performed twice as described above with the deprotection solution to prepare Arg (Pbf) -Tyr (tBu) -CTL Resin. After sufficient washing with DMF and MC, once again Kaiser test was performed, and the following amino acid attachment experiment was performed as above. Based on the selected amino acid sequence, chain reaction was performed in the order of Fmoc-Gly-OH, Fmoc-Gly-OH, Fmoc-Gly-OH, Fmoc-Trp-OH, and Fmoc-Lys (Boc) -OH. The Fmoc-protector was reacted twice with a deprotection solution twice for 10 minutes and then washed well.
- the peptidyl resin was washed three times with DMF, MC and methanol, and dried slowly by flowing nitrogen air, and then dried under reduced pressure under vacuum under P 2 O 5 to completely dry, followed by a fugitive solution (Trifluroacetic acid 81.5). %, Distilled water 5.0%, Thianisole 5.0%, Phenol 5.0%, EDT (EDT, Ethanedithiol) 2.5%, TIS (Tisopropylsilane) 1.0%] After adding 1,900 ml, shake at room temperature The reaction was maintained for 2 hours. The resin was filtered off and the resin was washed with a small amount of TFA solution and then combined with the mother liquor.
- Peptide consisting of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 3 was also synthesized in the same manner as described above.
- SEQ ID Nos. 1, 2, and 3 peptides were each mixed with a coating buffer (20 mM sodium phosphate pH 9.6) at a concentration of 1.8 mM and incubated at 4 ° C. overnight. Then, the cells were washed with PBST (Phosphate buffered saline with Tween-20) and blocked with 3% bovine serum albumin (BSA) for 2 hours at room temperature. Then, after washing with PBST again, 2,3,7,8-tetrachlorodibenzo-p-dioxin (hereinafter referred to as TCDD) was added 2 uM per well and incubated at room temperature for 2 hours.
- PBST Phosphate buffered saline with Tween-20
- BSA bovine serum albumin
- HaCaT a human keratinocyte
- 50uM peptide consisting of TCDD 10nM and amino acid sequences of SEQ ID NOs: 1, 2 or 3 was added to the medium, treated for 30 hours after the reaction for 1 hour, and the cells were recovered to separate nuclear and cytoplasmic proteins, respectively.
- Western blot using AhR (Aryl hydrocarbon receptor) antibody was performed to confirm activated AhR nuclear migration, and the results are shown in FIGS. 2A to 2F and Table 3.
- HaCaT a human keratinocyte
- TCDD 50 nM amino acid sequences of SEQ ID NOs: 1, 2 or 3
- 50 uM of peptide consisting of TCDD 50 nM and amino acid sequences of SEQ ID NOs: 1, 2 or 3 were added to the medium and treated for 5 minutes after reaction for 30 minutes, and fixed with 4% paraformaldehyde for 30 minutes. Then, after washing three times, reacted with 0.5% Triton X-100 for 15 minutes and washed three times.
- the peptide consisting of the amino acid sequence of SEQ ID NO: 1, 2 or 3 inhibited the influx of TCDD into the cell.
- HaCaT a human keratinocyte
- TCDD 10 nM amino acid sequences of SEQ ID NOs: 1, 2 or 3
- DCFH-DA DCFH-DA
- the peptide consisting of the amino acid sequence of SEQ ID NO: 1, 2 or 3 lowered the level of intracellular ROS increased by TCDD.
- HaCaT a human keratinocyte
- 50uM of peptide consisting of TCDD 10nM and amino acid sequence of SEQ ID NO: 1, 2 or 3 was added to the medium, and after 30 minutes reaction, the cells were treated for 6 hours or 24 hours, and the cells were recovered to separate RNA.
- cDNA was synthesized using cDNA synthesis kit (Intron, Korea), and PCR premix (Intron, Korea) and CYP1A1, TNF-a, IL-6, IL-1b, and COX-2 of Table 4, respectively. PCR was performed using the primers. Then, running on a 5% agarose gel to compare the mRNA expression of the growth factors in each sample treatment conditions, the results are shown in Figures 5a to 5c.
- the peptide consisting of the amino acid sequence of SEQ ID NO: 1, 2 or 3 showed the effect of inhibiting the expression of CYP1A1 and various inflammation-related factors induced by TCDD.
- HaCaT a human keratinocyte
- PM urban particulate matters
- 10 uM peptide consisting of amino acid sequences of SEQ ID NOs: 1, 2 or 3 were added to the medium, treated for 1 hour after the reaction for 30 minutes, and the cells were recovered to recover the nuclear and cytoplasmic proteins. Were separated respectively.
- Western blot using AhR (Aryl hydrocarbon receptor) antibody was performed to confirm activated AhR nuclear migration, and the results are shown in FIGS. 6A to 6C.
- the peptide consisting of the amino acid sequence of SEQ ID NO: 1, 2 or 3 inhibited AhR nuclear migration by fine dust.
- HaCaT a human keratinocyte
- a human keratinocyte was seeded in 6-well plates at a density of 3 ⁇ 10 5 cells / well and incubated overnight.
- 50 uM of peptide consisting of 10 nM of PM (Particulate matter) and amino acid sequences of SEQ ID NOs: 1, 2 or 3 was added to the medium, and after 30 minutes of reaction, the cells were treated for 6 hours or 24 hours, and the cells were recovered to separate RNA.
- RNA was quantified, cDNA was synthesized using a cDNA synthesis kit (Intron, Korea), PCR premix (Intron, Korea) and CYP1A1, TNF-a, IL-6, IL-1b, PCR was performed using primers for each of COX-2. Then, run on a 5% agarose gel to compare the mRNA expression level of the growth factors in each sample treatment conditions, the results are shown in Figure 7a to 7c.
- the peptide consisting of the amino acid sequence of SEQ ID NO: 1, 2 or 3 showed the effect of inhibiting the expression of CYP1A1 and various inflammation-related factors induced by fine dust.
- the present invention relates to a peptide having a cell protective effect against an environmental pollutant and its use.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Polymers & Plastics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
서열 번호 | 서열 목록 | 분석값(질량분석기) | |
분석치 | 이론치 | ||
1 | KWGGGRY | 822.9 | 822.9 |
2 | ILGRWCG | 803.9 | 803.9 |
3 | DVENTS | 663.6 | 663.6 |
서열번호 | 대조군 | 50 uM | 500 uM | 1000 uM | 2000 uM |
1 | 100 % | 193 % | 360 % | 394 % | 575 % |
2 | 100 % | 128 % | 264 % | 358 % | 405 % |
3 | 100 % | 159 % | 253 % | 400 % | 420 % |
서열번호 | 대조군 | TCDD | TCDD + 펩타이드 | |
5uM | 50 uM | |||
1 | 1배 | 5.8배 | 1.9배 | 1.9배 |
2 | 1배 | 5.7배 | 2.5배 | 0.9배 |
3 | 1배 | 5.9배 | 3배 | 1.5배 |
서열번호 | 프라이머 | 서열(5'-3') |
4 | CYP1A1_F | GGATCTTTCTCTGTACCCTGG |
5 | CYP1A1_R | AGCATGTCCTTCAGCCCAGA |
6 | TNF-a_F | CGTCAGCCGATTRTGCTATCT |
7 | TNF-a_R | CGGACTCCGCAAAGTCTAAG |
8 | IL-6_F | AAAGAGGCACTGCCAGAAAA |
9 | IL-6_R | ATCTGAGGTGCCCATGCTAC |
10 | IL-1b_F | TTCGACACATGGGATAACGA |
11 | IL-1b_R | TCTTTCAACACGCAGGACAG |
12 | COX-2_F | ATCATTCACCAGGCAAATTGC |
13 | COX-2_R | GGCTTCAGCATAAAGCGTTTG |
서열번호 | 프라이머 | 서열(5'-3') |
4 | CYP1A1_F | GGATCTTTCTCTGTACCCTGG |
5 | CYP1A1_R | AGCATGTCCTTCAGCCCAGA |
6 | TNF-a_F | CGTCAGCCGATTRTGCTATCT |
7 | TNF-a_R | CGGACTCCGCAAAGTCTAAG |
8 | IL-6_F | AAAGAGGCACTGCCAGAAAA |
9 | IL-6_R | ATCTGAGGTGCCCATGCTAC |
10 | IL-1b_F | TTCGACACATGGGATAACGA |
11 | IL-1b_R | TCTTTCAACACGCAGGACAG |
12 | COX-2_F | ATCATTCACCAGGCAAATTGC |
13 | COX-2_R | GGCTTCAGCATAAAGCGTTTG |
Claims (7)
- 서열번호 1, 2 또는 3의 아미노산 서열로 이루어진 펩타이드.
- 서열번호 1, 서열번호 2 또는 서열번호 3의 아미노산 서열로 이루어진 펩타이드로 이루어진 군에서 선택된 1종 이상의 펩타이드를 유효성분으로 포함하는 다이옥신 유사물질에 의해 유발되는 질병의 예방 또는 치료용 약제학적 조성물.
- 제2항에 있어서, 상기 다이옥신 유사물질에 의해 유발되는 질병은, 염소성 여드름과 같은 피부 질환, 정자수 감소, 고환암, 전립선암, 자궁내막 증식증, 유방암, 간독성, 면역기능 저하, 고지혈증, 요도하열, 잠복고한, 기형아 출산, 혈관 손상, 간세포성 암종, 간의 비대, 선섬유증, 체중 손실, 모발 손실, 구강 부종, 안검 부종 및 위점막성 궤양인 것인, 다이옥신 유사물질에 의해 유발되는 질병의 약제학적 조성물.
- 제2항에 있어서, 상기 다이옥신 유사물질은 폴리염소화 디벤조다이옥신(PCDD), 폴리염소화 디벤조퓨란(PDCF) 및 폴리염소화 비페닐(PCB)로 이루어진 군에서 선택된 1종 이상인 것인, 다이옥신 유사물질에 의해 유발되는 질병의 약제학적 조성물.
- 제4항에 있어서, 상기 폴리염소화 디벤조다이옥신은 2,3,7,8-테트라클로로디벤조다이옥신(TCDD)인 것인, 다이옥신 유사물질에 의해 유발되는 질병의 약제학적 조성물.
- 서열번호 1, 서열번호 2 또는 서열번호 3의 아미노산 서열로 이루어진 펩타이드로 이루어진 군에서 선택된 1종 이상의 펩타이드를 유효성분으로 포함하는 다이옥신 유사물질에 대한 길항성 식품 조성물.
- 서열번호 1, 서열번호 2 또는 서열번호 3의 아미노산 서열로 이루어진 펩타이드로 이루어진 군에서 선택된 1종 이상의 펩타이드를 유효성분으로 포함하는 피부상태 개선용 화장품 조성물.
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18774488.3A EP3611182B1 (en) | 2017-03-30 | 2018-02-14 | Peptide having cytoprotective effect against environmental pollutant and use thereof |
JP2019552607A JP6896094B2 (ja) | 2017-03-30 | 2018-02-14 | 環境汚染物質に対する細胞保護効果を有するペプチド及びその用途 |
ES18774488T ES2975420T3 (es) | 2017-03-30 | 2018-02-14 | Péptido que tiene efecto citoprotector contra contaminantes medioambientales y uso del mismo |
EA201992304A EA201992304A1 (ru) | 2017-03-30 | 2018-02-14 | Пептид, обладающий цитопротекторным эффектом против действия загрязняющих окружающую среду веществ, и его применение |
CN201880021782.3A CN110461864B (zh) | 2017-03-30 | 2018-02-14 | 具有抵抗环境污染物质的细胞保护效果的肽及其用途 |
US16/497,056 US11104704B2 (en) | 2017-03-30 | 2018-02-14 | Peptide having cytoprotective effect against environmental pollutant and use thereof |
BR112019020063A BR112019020063A2 (pt) | 2017-03-30 | 2018-02-14 | peptídeo que tem efeito citoprotetor contra poluente ambiental e seu uso |
US17/391,261 US11597748B2 (en) | 2017-03-30 | 2021-08-02 | Peptide having cytoprotective effect against environmental pollutant and use thereof |
US18/158,642 US11859016B2 (en) | 2017-03-30 | 2023-01-24 | Peptide having cytoprotective effect against environmental pollutant and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0040514 | 2017-03-30 | ||
KR1020170040514A KR101943083B1 (ko) | 2017-03-30 | 2017-03-30 | 환경오염 물질에 대한 세포 보호 효과를 갖는 펩타이드 및 이의 용도 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/497,056 A-371-Of-International US11104704B2 (en) | 2017-03-30 | 2018-02-14 | Peptide having cytoprotective effect against environmental pollutant and use thereof |
US17/391,261 Continuation US11597748B2 (en) | 2017-03-30 | 2021-08-02 | Peptide having cytoprotective effect against environmental pollutant and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018182172A1 true WO2018182172A1 (ko) | 2018-10-04 |
Family
ID=63676649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/001953 WO2018182172A1 (ko) | 2017-03-30 | 2018-02-14 | 환경오염 물질에 대한 세포 보호 효과를 갖는 펩타이드 및 이의 용도 |
Country Status (9)
Country | Link |
---|---|
US (3) | US11104704B2 (ko) |
EP (1) | EP3611182B1 (ko) |
JP (1) | JP6896094B2 (ko) |
KR (1) | KR101943083B1 (ko) |
CN (1) | CN110461864B (ko) |
BR (1) | BR112019020063A2 (ko) |
EA (1) | EA201992304A1 (ko) |
ES (1) | ES2975420T3 (ko) |
WO (1) | WO2018182172A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3904369A4 (en) * | 2019-02-20 | 2022-11-23 | Caregen Co., Ltd. | PEPTIDE FOR THE PREVENTION OF SKIN DAMAGE CAUSED BY ATMOSPHERIC POLLUTANTS AND FOR THE FIGHT AGAINST AGING, AND USE IN RELATION |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101943083B1 (ko) | 2017-03-30 | 2019-01-29 | (주)케어젠 | 환경오염 물질에 대한 세포 보호 효과를 갖는 펩타이드 및 이의 용도 |
KR101943081B1 (ko) | 2017-08-31 | 2019-01-29 | (주)케어젠 | 주름 개선 활성을 나타내는 펩타이드 및 이의 용도 |
KR102114275B1 (ko) * | 2018-11-07 | 2020-05-25 | 제주대학교 산학협력단 | C-펩타이드를 유효성분으로 포함하는 미세먼지에 대한 피부보호용 화장료 조성물 |
KR102351515B1 (ko) * | 2019-12-17 | 2022-01-14 | (주)수파드엘릭사 | 아릴 탄화수소 수용체의 활성을 억제하는 폡타이드 및 이를 이용하는 화장료 조성물 |
KR102539445B1 (ko) * | 2020-11-25 | 2023-06-05 | (주)케어젠 | 미세먼지에 의한 세포 손상 방지 활성을 갖는 펩타이드 및 이의 용도 |
KR102474470B1 (ko) * | 2020-11-25 | 2022-12-07 | (주)케어젠 | 미세먼지에 의한 세포 손상 방지 활성을 갖는 펩타이드 및 이의 용도 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5516891A (en) | 1992-06-16 | 1996-05-14 | Kinerton, Ltd. | Liquid phase synthesis of peptides and peptide derivatives |
JP2003231697A (ja) * | 2002-02-06 | 2003-08-19 | Japan Science & Technology Corp | ダイオキシントラッピング能を有するタンパク質 |
KR20060035432A (ko) * | 2004-10-22 | 2006-04-26 | 한국생명공학연구원 | 다이옥신 노출 여부 진단용 마커 및 이를 이용하여 다이옥신 노출을 확인하는 방법 |
US20080038838A1 (en) * | 2003-10-10 | 2008-02-14 | Towa Kagaku Co., Ltd. | Dioxin-Binding Material and Method of Detecting or Quantifying Dioxin |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999042565A1 (en) * | 1997-05-31 | 1999-08-26 | Hoechst Schering Agrevo Gmbh | Herbicides test method |
US6783953B1 (en) | 1998-12-22 | 2004-08-31 | Janssen Pharmaceutica N.V. | Vascular endothelial growth factor-X |
KR100480972B1 (ko) * | 2001-03-24 | 2005-05-06 | (주)내츄럴엔도텍 | 초피나무 추출물을 유효성분으로 하는 다이옥신유사물질에 대한 길항성 조성물 |
KR100480971B1 (ko) * | 2001-03-24 | 2005-05-17 | (주)내츄럴엔도텍 | 정향 추출물을 유효성분으로 하는 다이옥신 유사물질에대한 길항성 조성물 |
US8344211B2 (en) * | 2008-08-13 | 2013-01-01 | Ceres, Inc. | Plant nucleotide sequences and corresponding polypeptides |
US20060045902A1 (en) * | 2004-09-01 | 2006-03-02 | Serbousek Jon C | Polymeric wrap for in vivo delivery of osteoinductive formulations |
US8088976B2 (en) * | 2005-02-24 | 2012-01-03 | Monsanto Technology Llc | Methods for genetic control of plant pest infestation and compositions thereof |
CN101400699A (zh) * | 2006-01-11 | 2009-04-01 | 布里斯托尔-迈尔斯·斯奎布公司 | 人胰高血糖素样肽-1调节剂及其在治疗糖尿病和相关病症中的用途 |
US20140343129A1 (en) * | 2011-12-14 | 2014-11-20 | Moderna Therapeutics, Inc. | Modified nucleic acids, and acute care uses thereof |
US8877434B2 (en) * | 2012-04-19 | 2014-11-04 | Hsinyu Lee | Method and system of detecting dioxin-like compounds |
NZ700274A (en) * | 2012-04-24 | 2016-10-28 | Thrombogenics Nv | Anti-pdgf-c antibodies |
KR101510742B1 (ko) * | 2013-05-13 | 2015-04-10 | (주)케어젠 | 비만세포―특이적 아팝토시스-유도용 펩타이드 및 이의 용도 |
KR101632948B1 (ko) * | 2014-05-13 | 2016-06-27 | (주)케어젠 | 항염증, 골 형성 및 발모 촉진 활성을 갖는 펩타이드 및 이의 용도 |
KR101943083B1 (ko) | 2017-03-30 | 2019-01-29 | (주)케어젠 | 환경오염 물질에 대한 세포 보호 효과를 갖는 펩타이드 및 이의 용도 |
KR101943081B1 (ko) * | 2017-08-31 | 2019-01-29 | (주)케어젠 | 주름 개선 활성을 나타내는 펩타이드 및 이의 용도 |
-
2017
- 2017-03-30 KR KR1020170040514A patent/KR101943083B1/ko active IP Right Grant
-
2018
- 2018-02-14 EP EP18774488.3A patent/EP3611182B1/en active Active
- 2018-02-14 CN CN201880021782.3A patent/CN110461864B/zh active Active
- 2018-02-14 ES ES18774488T patent/ES2975420T3/es active Active
- 2018-02-14 BR BR112019020063A patent/BR112019020063A2/pt unknown
- 2018-02-14 US US16/497,056 patent/US11104704B2/en active Active
- 2018-02-14 JP JP2019552607A patent/JP6896094B2/ja active Active
- 2018-02-14 EA EA201992304A patent/EA201992304A1/ru unknown
- 2018-02-14 WO PCT/KR2018/001953 patent/WO2018182172A1/ko unknown
-
2021
- 2021-08-02 US US17/391,261 patent/US11597748B2/en active Active
-
2023
- 2023-01-24 US US18/158,642 patent/US11859016B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5516891A (en) | 1992-06-16 | 1996-05-14 | Kinerton, Ltd. | Liquid phase synthesis of peptides and peptide derivatives |
JP2003231697A (ja) * | 2002-02-06 | 2003-08-19 | Japan Science & Technology Corp | ダイオキシントラッピング能を有するタンパク質 |
US20080038838A1 (en) * | 2003-10-10 | 2008-02-14 | Towa Kagaku Co., Ltd. | Dioxin-Binding Material and Method of Detecting or Quantifying Dioxin |
KR20060035432A (ko) * | 2004-10-22 | 2006-04-26 | 한국생명공학연구원 | 다이옥신 노출 여부 진단용 마커 및 이를 이용하여 다이옥신 노출을 확인하는 방법 |
Non-Patent Citations (10)
Title |
---|
"Fourth Annual Report on Carcinogens, NTP 85-002:170", vol. 185, 1985 |
"Remington's Pharmaceutical Sciences", 1995 |
CARTER ET AL., SCIENCE, vol. 188, 1975, pages 738 |
LEE, Y. W. ET AL., TOXICOL. LETT., vol. 102-103, 1998, pages 29 - 83 |
MERRIFIELD, J. AMER. CHEM. SOC., vol. 85, 1963, pages 2149 - 54 |
NAKAMURA, CHIKASHI: "Dioxin-binding pentapeptide for use in a high- sensitivity on-bead detection assay", ANALYTICAL CHEMISTRY, vol. 77, no. 23, 29 October 2005 (2005-10-29) - 1 December 2005 (2005-12-01), pages 7750 - 7757, XP055612579 * |
PANDINI, ALESSANDRO: "Detection of the TCDD binding-fingerprint within the Ah receptor ligand binding domain by structurally driven mutagenesis and functional analysis", BIOCHEMISTRY, vol. 48, no. 25, 30 June 2009 (2009-06-30), pages 5972 - 5983, XP055612586 * |
See also references of EP3611182A4 |
STEWART ET AL.: "Solid Phase Peptide Synthesis", vol. 111, 1984, PIERCE CHEM. CO. |
YANG, J. H. ET AL., CARCINOGENESIS, vol. 20, 1999, pages 13 - 18 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3904369A4 (en) * | 2019-02-20 | 2022-11-23 | Caregen Co., Ltd. | PEPTIDE FOR THE PREVENTION OF SKIN DAMAGE CAUSED BY ATMOSPHERIC POLLUTANTS AND FOR THE FIGHT AGAINST AGING, AND USE IN RELATION |
Also Published As
Publication number | Publication date |
---|---|
CN110461864A (zh) | 2019-11-15 |
EA201992304A1 (ru) | 2020-02-25 |
JP6896094B2 (ja) | 2021-06-30 |
US11597748B2 (en) | 2023-03-07 |
US11104704B2 (en) | 2021-08-31 |
EP3611182A1 (en) | 2020-02-19 |
ES2975420T3 (es) | 2024-07-05 |
US11859016B2 (en) | 2024-01-02 |
BR112019020063A2 (pt) | 2020-04-28 |
KR101943083B1 (ko) | 2019-01-29 |
EP3611182A4 (en) | 2020-10-28 |
EP3611182B1 (en) | 2024-02-14 |
US20230227501A1 (en) | 2023-07-20 |
JP2020515547A (ja) | 2020-05-28 |
US20210371464A1 (en) | 2021-12-02 |
US20200377550A1 (en) | 2020-12-03 |
KR20180112140A (ko) | 2018-10-12 |
CN110461864B (zh) | 2023-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018182172A1 (ko) | 환경오염 물질에 대한 세포 보호 효과를 갖는 펩타이드 및 이의 용도 | |
EP0915910B1 (de) | Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel | |
WO2013169060A1 (ko) | 패혈증 예방 또는 치료용 조성물 | |
EP2709645B1 (en) | Improved peptide pharmaceuticals | |
CN118324870A (zh) | 用于胰岛素抗性的改良的肽药物 | |
WO2014046478A1 (ko) | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 | |
WO2020171285A1 (ko) | 대기오염물질에 의한 피부 손상 방지 및 항노화용 펩타이드와 이의 용도 | |
FI68246B (fi) | Analogifoerfarande foer framstaellning av nya cyklopeptider | |
EP0395417A1 (en) | Linear somatostatin analogues | |
WO2017142264A1 (ko) | 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도 | |
WO2018216884A1 (ko) | 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도 | |
CA2010660A1 (en) | Osteogenic growth polypeptides identified from regenerating bone marrow | |
EA042132B1 (ru) | Пептид, обладающий цитопротекторным эффектом против действия загрязняющих окружающую среду веществ, и его применение | |
WO2024106585A1 (ko) | 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도 | |
WO2024106588A1 (ko) | 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도 | |
WO2022114261A1 (ko) | 미세먼지에 의한 세포 손상 방지 활성을 갖는 펩타이드 및 이의 용도 | |
WO2022114260A1 (ko) | 미세먼지에 의한 세포 손상 방지 활성을 갖는 펩타이드 및 이의 용도 | |
WO2023127986A1 (ko) | 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도 | |
WO2023127984A1 (ko) | 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도 | |
WO2023127985A1 (ko) | 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도 | |
WO2023127987A1 (ko) | 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도 | |
WO2024122713A1 (ko) | 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도 | |
WO2024106586A1 (ko) | 발모 촉진 및 탈모 억제 활성을 갖는 펩타이드 및 이의 용도 | |
WO2024122719A1 (ko) | 연골 재생용 펩타이드 및 이의 용도 | |
JP2812803B2 (ja) | 有機保護活性を備えたペプチド |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18774488 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019552607 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019020063 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2018774488 Country of ref document: EP Effective date: 20191030 |
|
ENP | Entry into the national phase |
Ref document number: 112019020063 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190925 |